We have stopped collecting the information and will no longer provide updates to the WTO-IMF COVID-19 Vaccine Trade Tracker.
WTO-IMF COVID-19 Vaccine Trade Tracker
Fast and smooth cross-border movement of vaccines, vaccine inputs and related supplies is essential for the world to achieve its vaccination targets without delay.
The WTO-IMF Vaccine Trade Tracker provides data on the trade and supply of COVID-19 vaccines by product, economy and arrangement type. The tracker builds on the work of the WTO Secretariat information notes on COVID-19 and world trade and the IMF Staff Discussion Note – A Proposal to End the COVID-19 Pandemic (Agarwal and Gopinath, 2021).
This Tracker shows the supply of vaccine doses from facilities where the final vaccines are made (where "fill and finish" is completed) to the economies where they are administered; cases where production facilities are located within destination economies are referred to as "domestic supply". For vaccines that only require one dose (J&J and CanSino), volumes are doubled to make them comparable with two-shot vaccines. This should be considered when comparing these numbers to other sources.
1. Summary
As of 31 May 2022
Total supply to date: 15.2 billion doses
   Domestic supply: 9.0 billion doses
   Implicit trade (exports or imports): 6.2 billion doses
2. Exports
Exports are defined as the number of doses delivered across borders from producing economies to economies where vaccines are administered.
By producing economy
This Tracker defines a "producing economy" as a country or territory where final vaccines are made or where "fill and finish" is completed. This definition does not take into account exports of vaccine substances in bulk form shipped to "fill and finish" sites located in other countries or territories.
    Total number of doses exported by producing economy
|
Producing economy
|
Number of doses (million)
|
Share of world exports
|
Cumulative share
|
Exports as share of total supply
|
|
European Union
|
2,440.4
|
39.6%
|
39.6%
|
65.6%
|
|
China
|
1,986.4
|
32.2%
|
71.8%
|
32.7%
|
|
United States of America
|
968.0
|
15.7%
|
87.5%
|
60.1%
|
|
Korea, Republic of
|
240.4
|
3.9%
|
91.4%
|
91.2%
|
|
India
|
140.2
|
2.3%
|
93.6%
|
5.7%
|
|
South Africa
|
110.4
|
1.8%
|
95.4%
|
88.2%
|
|
Russian Federation
|
102.4
|
1.7%
|
97.1%
|
35.8%
|
|
Japan
|
67.0
|
1.1%
|
98.2%
|
79.0%
|
|
Other
|
113.4
|
1.8%
|
100.0%
|
|
|
Note: as of 31 May 2022
|
By supply arrangement type
This Tracker identifies five different arrangements through which the vaccines can reach the destination economies (not including domestic supply). These arrangements are 1) contracted supply via COVAX; 2) donations via COVAX; 3) supply via bilateral deals; 4) direct donations; and 5) supply via AVAT (African Vaccine Acquisition Trust).
    Total number of doses exported by arrangement type
|
Supply arrangement type
|
Number of doses (million)
|
Share
|
Cumulative share
|
|
Supply via bilateral deals
|
4,199.7
|
68.1%
|
68.1%
|
|
Donations via COVAX
|
829.2
|
13.4%
|
81.5%
|
|
Contracted supply via COVAX
|
618.6
|
10%
|
91.6%
|
|
Direct donations
|
409.2
|
6.6%
|
98.2%
|
|
Supply via AVAT
|
111.8
|
1.8%
|
100.0%
|
|
Note: as of 31 May 2022
|
3. Imports
Imports are defined as the number of doses received from producing economies, mirroring the information provided in the exports section. This definition does not take into account imports of vaccine substances in bulk form to be used in "fill and finish" sites.
By income group
    Total number of doses imported by income group
|
Income Group Imports
|
Number of doses (million)
|
Doses per 100 people
|
Population (million)
|
|
Low income
|
390.6
|
55.5
|
704.3
|
|
Lower middle income
|
2,206.5
|
73.7
|
2,995.4
|
|
Upper middle income
|
2,376.2
|
81.1
|
2,930.4
|
|
High income
|
1,195.3
|
96.0
|
1,244.6
|
|
Note: as of 31 May 2022
|
By Continent
    Number of doses imported by continent
|
Continent
|
Number of doses (million)
|
Doses per 100 people
|
Population (million)
|
|
Asia
|
3,273.5
|
70.0
|
4,678.5
|
|
South America
|
1,019.5
|
234.9
|
434.0
|
|
Africa
|
955.8
|
69.6
|
1,372.3
|
|
North America
|
561.0
|
94.2
|
595.8
|
|
Europe
|
290.9
|
38.7
|
750.7
|
|
Oceania
|
68.0
|
156.5
|
43.4
|
|
Note: as of 31 May 2022
|
4. Total Supply
Total supply contains both exported and domestically delivered doses.
By producing economy
    Total supply by producing economy
|
Producing economy
|
Number of doses (million)
|
Share
|
Cumulative Share
|
Population (million)
|
|
China
|
6,077.3
|
40.1%
|
40.1%
|
1,444.2
|
|
European Union
|
3,721.0
|
24.6%
|
64.7%
|
447.0
|
|
India
|
2,465.6
|
16.3%
|
80.9%
|
1,393.4
|
|
United States of America
|
1,609.8
|
10.6%
|
91.6%
|
332.9
|
|
Russian Federation
|
286.2
|
1.9%
|
93.4%
|
145.9
|
|
Korea, Republic of
|
263.5
|
1.7%
|
95.2%
|
51.3
|
|
Brazil
|
172.3
|
1.1%
|
96.3%
|
214.0
|
|
Mexico
|
138.2
|
0.9%
|
97.2%
|
130.3
|
|
South Africa
|
125.2
|
0.8%
|
98.1%
|
60.0
|
|
Thailand
|
95.1
|
0.6%
|
98.7%
|
70.0
|
|
Other
|
198.9
|
1.3%
|
100.0%
|
|
|
Note: as of 31 May 2022
|
By vaccine type
    Total supply by vaccine type
|
Vaccine
|
Number of doses (million)
|
Share
|
Cumulative Share
|
|
AstraZeneca
|
3,465.6
|
22.9%
|
22.9%
|
|
Sinovac
|
3,165.3
|
20.9%
|
43.8%
|
|
Pfizer
|
3,097.7
|
20.4%
|
64.2%
|
|
Sinopharm
|
2,851.8
|
18.8%
|
83.0%
|
|
Moderna
|
1,045.2
|
6.9%
|
89.9%
|
|
J&J
|
878.2
|
5.8%
|
95.7%
|
|
Sputnik V
|
310.1
|
2.0%
|
97.8%
|
|
Other
|
339.1
|
2.2%
|
100.0%
|
|
Note: as of 31 May 2022
|
5. Supply to Continents
Africa
Total doses received: 970.8 million
    Supply by arrangement type
|
Arrangement type
|
Number of doses (million)
|
Share
|
|
Contracted supply via COVAX
|
208.8
|
21.5%
|
|
Direct donations
|
67.4
|
6.9%
|
|
Domestic supply
|
15.0
|
1.5%
|
|
Donations via COVAX
|
447.8
|
46.1%
|
|
Supply via AVAT
|
110.4
|
11.4%
|
|
Supply via bilateral deals
|
121.4
|
12.5%
|
|
Total
|
970.8
|
|
|
Note: as of 31 May 2022
|
    Supply by producing economy
|
Source
|
Total number of doses
|
Contracted supply via COVAX
|
Direct donations
|
Domestic supply
|
Donations via COVAX
|
Supply via AVAT
|
Supply via bilateral deals
|
|
United States of America
|
466,087,411
|
92,937,192
|
9,215,770
|
-
|
359,030,460
|
-
|
4,903,989
|
|
European Union
|
155,919,716
|
43,813,566
|
21,952,160
|
-
|
69,978,944
|
-
|
20,175,045
|
|
China
|
142,196,662
|
32,576,800
|
32,597,810
|
-
|
-
|
-
|
77,022,052
|
|
South Africa
|
125,175,547
|
-
|
-
|
14,770,437
|
-
|
110,381,800
|
23,310.32
|
|
India
|
39,202,000
|
22,243,000
|
1,005,000
|
-
|
-
|
-
|
15,954,000
|
|
Other
|
42,199,521
|
17,248,000
|
2,598,850
|
238,856.4
|
18,777,656
|
-
|
3,336,159
|
|
Total
|
970,780,858
|
208,818,558
|
67,369,590
|
15,009,293
|
447,787,060
|
110,381,800
|
121,414,556
|
|
Note: as of 31 May 2022
|
Asia
Total doses received: 9,811.3 million
    Supply by arrangement type
|
Arrangement type
|
Number of doses (million)
|
Share
|
|
Contracted supply via COVAX
|
290.9
|
3%
|
|
Direct donations
|
251.2
|
2.6%
|
|
Domestic supply
|
6,537.8
|
66.6%
|
|
Donations via COVAX
|
337.2
|
3.4%
|
|
Supply via bilateral deals
|
2,394.2
|
24.4%
|
|
Total
|
9,811.3
|
|
|
Note: as of 31 May 2022
|
    Supply by producing economy
|
Source
|
Total number of doses
|
Contracted supply via COVAX
|
Direct donations
|
Domestic supply
|
Donations via COVAX
|
Supply via bilateral deals
|
|
China
|
5,485,166,671
|
43,540,000
|
83,518,000
|
4,090,889,843
|
-
|
1,267,218,827
|
|
India
|
2,401,823,171
|
15,047,300
|
12,237,000
|
2,325,391,071
|
-
|
49,147,800
|
|
European Union
|
1,169,327,454
|
97,504,104
|
37,344,369
|
-
|
140,913,588
|
893,565,393
|
|
United States of America
|
342,436,968
|
107,037,184
|
61,357,040
|
-
|
167,176,844
|
6,865,900
|
|
Korea, Republic of
|
168,827,864
|
27,768,600
|
-
|
23,085,614
|
-
|
117,973,650
|
|
Other
|
243,716,796
|
-
|
56,753,371
|
98,383,905
|
29,111,410
|
59,468,110
|
|
Total
|
9,811,298,923
|
290,897,188
|
251,209,780
|
6,537,750,434
|
337,201,842
|
2,394,239,679
|
|
Note: as of 31 May 2022
|
Europe
Total doses received: 1,794.2 million
    Supply by arrangement type
|
Arrangement type
|
Number of doses (million)
|
Share
|
|
Contracted supply via COVAX
|
9.4
|
0.5%
|
|
Direct donations
|
12.0
|
0.7%
|
|
Domestic supply
|
1,503.4
|
83.8%
|
|
Donations via COVAX
|
4.2
|
0.2%
|
|
Supply via bilateral deals
|
265.2
|
14.8%
|
|
Total
|
1,794.2
|
|
|
Note: as of 31 May 2022
|
    Supply by producing economy
|
Source
|
Total number of doses
|
Contracted supply via COVAX
|
Direct donations
|
Domestic supply
|
Donations via COVAX
|
Supply via bilateral deals
|
|
European Union
|
1,509,086,351
|
1,359,297
|
6,240,040
|
1,280,577,216
|
871,951.2
|
220,037,847
|
|
Russian Federation
|
185,783,691
|
-
|
259,000
|
183,838,160
|
-
|
1,686,531
|
|
China
|
38,298,744
|
465,600
|
4,428,000
|
-
|
-
|
33,405,144
|
|
United Kingdom
|
37,955,460
|
-
|
-
|
37,955,460
|
-
|
-
|
|
United States of America
|
9,791,777
|
5,437,187
|
1,015,585
|
-
|
3,339,005
|
-
|
|
Other
|
13,310,086
|
2,162,400
|
50,000
|
986,864.8
|
-
|
10,110,821
|
|
Total
|
1,794,226,109
|
9,424,484
|
11,992,625
|
1,503,357,701
|
4,210,956
|
265,240,344
|
|
Note: as of 31 May 2022
|
North America
Total doses received: 1,294.6 million
    Supply by arrangement type
|
Arrangement type
|
Number of doses (million)
|
Share
|
|
Contracted supply via COVAX
|
35.8
|
2.8%
|
|
Direct donations
|
33.5
|
2.6%
|
|
Domestic supply
|
733.6
|
56.7%
|
|
Donations via COVAX
|
17.6
|
1.4%
|
|
Supply via AVAT
|
1.4
|
0.1%
|
|
Supply via bilateral deals
|
472.6
|
36.5%
|
|
Total
|
1,294.6
|
|
|
Note: as of 31 May 2022
|
    Supply by producing economy
|
Source
|
Total number of doses
|
Contracted supply via COVAX
|
Direct donations
|
Domestic supply
|
Donations via COVAX
|
Supply via AVAT
|
Supply via bilateral deals
|
|
United States of America
|
704,914,621
|
6,197,342
|
7,533,013
|
641,836,820
|
10,999,936
|
-
|
38,347,510
|
|
European Union
|
352,174,459
|
1,549,336
|
21,932,664
|
-
|
6,643,726
|
1,401,600
|
320,647,133
|
|
Mexico
|
93,241,826
|
-
|
1,433,862
|
91,807,964
|
-
|
-
|
-
|
|
China
|
77,255,307
|
222,000
|
1,330,000
|
-
|
-
|
-
|
75,703,307
|
|
Korea, Republic of
|
37,108,201
|
27,716,100
|
-
|
-
|
-
|
-
|
9,392,101
|
|
Other
|
29,920,440
|
135,000
|
1,307,481
|
-
|
-
|
-
|
28,477,959
|
|
Total
|
1,294,614,854
|
35,819,778
|
33,537,020
|
733,644,784
|
17,643,662
|
1,401,600
|
472,568,010
|
|
Note: as of 31 May 2022
|
Oceania
Total doses received: 82.7 million
    Supply by arrangement type
|
Arrangement type
|
Number of doses (million)
|
Share
|
|
Contracted supply via COVAX
|
1.5
|
1.8%
|
|
Direct donations
|
2.3
|
2.8%
|
|
Domestic supply
|
14.7
|
17.8%
|
|
Donations via COVAX
|
2.7
|
3.3%
|
|
Supply via bilateral deals
|
61.5
|
74.4%
|
|
Total
|
82.7
|
|
|
Note: as of 31 May 2022
|
    Supply by producing economy
|
Source
|
Total number of doses
|
Contracted supply via COVAX
|
Direct donations
|
Domestic supply
|
Donations via COVAX
|
Supply via bilateral deals
|
|
European Union
|
52,450,636
|
189,198
|
245,479.1
|
-
|
281,960
|
51,733,999
|
|
Australia
|
16,031,361
|
-
|
1,315,701
|
14,715,660
|
-
|
-
|
|
India
|
9,578,100
|
156,000
|
110,000
|
-
|
-
|
9,312,100
|
|
United States of America
|
2,907,854
|
756,792
|
37,850
|
-
|
2,113,212
|
-
|
|
China
|
675,079.3
|
-
|
620,000
|
-
|
-
|
55,079.34
|
|
Other
|
1,062,053
|
350,400
|
2,600
|
-
|
305,968
|
403,085.4
|
|
Total
|
82,705,084
|
1,452,390
|
2,331,630
|
14,715,660
|
2,701,140
|
61,504,264
|
|
Note: as of 31 May 2022
|
South America
Total doses received: 1,199.5 million
    Supply by arrangement type
|
Arrangement type
|
Number of doses (million)
|
Share
|
|
Contracted supply via COVAX
|
72.2
|
6%
|
|
Direct donations
|
42.8
|
3.6%
|
|
Domestic supply
|
180.0
|
15%
|
|
Donations via COVAX
|
19.7
|
1.6%
|
|
Supply via AVAT
|
0.1
|
0%
|
|
Supply via bilateral deals
|
884.8
|
73.8%
|
|
Total
|
1,199.5
|
|
|
Note: as of 31 May 2022
|
    Supply by producing economy
|
Source
|
Total number of doses
|
Contracted supply via COVAX
|
Direct donations
|
Domestic supply
|
Donations via COVAX
|
Supply via AVAT
|
Supply via bilateral deals
|
|
European Union
|
482,013,817
|
2,745,709
|
10,237,300
|
-
|
7,832,537
|
62,400
|
461,135,871
|
|
China
|
333,740,983
|
40,265,000
|
8,792,820
|
-
|
-
|
-
|
284,683,163
|
|
Brazil
|
172,344,788
|
-
|
-
|
172,344,788
|
-
|
-
|
-
|
|
United States of America
|
83,668,704
|
10,982,837
|
21,926,480
|
-
|
11,850,307
|
-
|
38,909,080
|
|
Mexico
|
44,987,923
|
-
|
1,412,000
|
-
|
-
|
-
|
43,575,923
|
|
Other
|
82,736,957
|
18,189,600
|
414,800
|
7,685,399
|
-
|
-
|
56,447,158
|
|
Total
|
1,199,493,172
|
72,183,146
|
42,783,400
|
180,030,187
|
19,682,844
|
62,400
|
884,751,195
|
|
Note: as of 31 May 2022
|
6. Vaccination Status
A course is defined as a series of vaccine doses required to be fully vaccinated. For COVID-19 vaccines that require two shots, the number of courses is the number of vaccine doses divided by two. For COVID-19 vaccines that require only one shot, the number of courses is the number of vaccine doses.
By income group
|
Income group
|
Number of doses supplied (million)
|
Number of courses supplied per 100 people
|
Percent with at least one dose administered
|
Percent fully vaccinated
|
Population (million)
|
|
Low income
|
390.6
|
27.7
|
17.3%
|
14.1%
|
704.3
|
|
Lower middle income
|
4,543.7
|
75.8
|
59.3%
|
51.8%
|
2,995.4
|
|
Upper middle income
|
7,007.6
|
119.6
|
79.1%
|
73.9%
|
2,930.4
|
|
High income
|
3,211.2
|
129.0
|
78.6%
|
73.8%
|
1,244.6
|
|
Note: as of 31 May 2022
|
By Continent
|
Continent
|
Number of doses supplied (million)
|
Number of courses supplied per 100 people
|
Percent with at least one dose administered
|
Percent fully vaccinated
|
Population (million)
|
|
Asia
|
9,811.3
|
104.9
|
75.5%
|
69.8%
|
4,678.5
|
|
Europe
|
1,794.2
|
119.5
|
68.1%
|
65.4%
|
750.7
|
|
North America
|
1,294.6
|
108.7
|
72.5%
|
63.6%
|
595.8
|
|
South America
|
1,199.5
|
138.2
|
84.5%
|
75.0%
|
434.0
|
|
Africa
|
970.8
|
35.4
|
23.4%
|
18.0%
|
1,372.3
|
|
Oceania
|
82.7
|
95.2
|
66.6%
|
63.6%
|
43.4
|
|
Note: as of 31 May 2022
|
Sources and Notes
This database draws information from the public domain, COVAX Global Vaccine Market Assessment, the United Nations Children’s Emergency Fund (UNICEF), Duke Global Health Innovation Center, Our World in Data, the World Bank Group, Asian Development Bank, and African Vaccine Acquisition Task Team (AVATT).
This data is preliminary and will be subject to revisions in collaboration with economies and areas, suppliers, immunization, health and financing partners. This tracker is updated every week to reflect latest developments. For additional information or inquiries, please contact [email protected] or [email protected].
Disclaimer
The WTO and IMF accept no responsibility whatsoever for any inaccurate or incomplete information or data that may be included in this database, and expressly disclaims any liability for damages as a result of its use. The responsibility for the interpretation and use of the content lies with the user. The WTO and IMF assume no responsibility or liability for any consequence resulting directly or indirectly from any action or inaction users take based on or made in reliance on the information and data available in this database.
The designations employed and the presentation of the material in this WTO-IMF COVID-19 Vaccine Trade Tracker follow exclusively the institutional style and practice of the WTO, and may be at variance with those used by IMF. The material presented in WTO-IMF COVID-19 Vaccine Trade Tracker does not imply the expression of any opinion whatsoever on the part of IMF and WTO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
